Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis

Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis


June 8, 2011
95 Pages - SKU: RNBR6404043
License type:
Online Download      US $950.00
Hard Copy Mail Delivery      US $1,050.00
CD-ROM Mail Delivery      US $1,050.00
Global Site License      US $1,700.00
Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis

  enlarge
Alzheimer’s Disease - Market Overview

Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, but it still remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments. Currently there’s no cure for Alzheimer’s and its still waiting for its key product. In addition, all current marketed products are going to be generic in the next five years.

In 2010, there were more than 30 Million people suffering with Alzheimer’s disease but it is anticipated that by 2015 over 35 Million people worldwide will be suffering from this disease. Much of this increase will be due to increase in number of people with Alzheimer’s in low and middle income countries. Since the risk of getting the disease increases with age, the number of patients with the illness to be found in any community will depend on the proportion of older people in the group. Traditionally, the developed countries have large proportions of elderly people, and so they have many cases of Alzheimer’s disease in the community at one time. However, developing countries are also undergoing a demographic transition so that more and more persons are surviving to an old age.

Global Alzheimer’s disease has increased manifold and expected to cross US$ 19 Billion by 2015. North America controls more than 50% of the total Alzheimer’s drug market share in 2010. Over the past years, the Alzheimer’s disease market has been flagged with several drugs into the market. Till last year Aricept was the world best selling drug which lost patent protection in November 2010, a milestone that will be followed by a rapid loss in sales. But there are other drugs which has the potential to become blockbuster drug by 2010. Namenda, Exelon has shown alluring growth in the market and become blockbusters in 2010. Ebixa a drug of Memantine group is expected to have a Billion dollar market by 2014. Given the alarming worldwide growth in Alzheimer’s patients, and especially if companies are able to address major unmet needs, the outlook for the Alzheimer’s disease market is excellent.


Additional Information

Report Details

Renub Research report titled “Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis” studies the Alzheimer’s Disease patients prevalence worldwide and region wise. The report provides data on the Alzheimer’s Disease market Worldwide, North America, Europe and Rest of the world.

Alzheimer’s drugs such as Exelon, Aricept, Namenda, Razadyne, Axura, Ebixa, Nootropil, Prometax, Memac, Eranz market past, present and future scenario has been analyzed in this report.

Key questions answered in the report?
  • Which regions have the highest prevalence of Alzheimer’s Disease diseases today and by 2050?
  • What is the market share accounted by Alzheimer’s disease drugs in the global markets?
  • What is the market share accounted by the region in the global market?
  • Which drugs have patent expiry and future forecast of drug sales?
Research Highlights
  • More than 35 Million people are expected to suffer from Alzheimer’s disease by 2015 worldwide.
  • By 2050, 59 percent of the world’s Alzheimer’s cases will live in Asia.
  • Global Alzheimer’s disease market is expected to cross the figure of US$ 19 Billion by 2015.
  • North America is the leading market share taker in the Alzheimer’s disease market.
  • Aricept sales is expected to fall after losing its patent in November 2010
  • Ebixa, Excelon & Namenda are on the path of becoming the next blockbuster drugs after Aricept
Key Company Profiles

This section provides business overview and key financial information of the companies listed below: Forest Laboratories, Eisai, H. Lundbeck A/S, Novartis, Merz GmbH & Co. KGaA, Johnson & Johnson, UCB

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

More CNS/Neurology reports by Renub Research

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015) by Renub Research
Schizophrenia - Market Overview Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as ...
See all reports like this >>